Global Cancer Biologics Market 2019-2023

Global Cancer Biologics Market 2019-2023

About this market

The rising global incidences of cancer are likely to impact the market’s growth during the forecast period. Increasing prevalence of environmental factors including tobacco smoking and pollution and changing dietary patterns are expected to contribute directly to the increased global incidences of cancer. Such rising incidences of this condition will eventually contribute to the cancer biologics market growth during the forecast period. Technavio’s analysts have predicted that the cancer biologics market will register a CAGR of over 11% by 2023.

Market Overview

The rising global incidence of cancer

The major etiological factors leading to cancer include genetic mutations, environmental factors such as tobacco smoking and pollution, and changing dietary patterns. The rising prevalence of these factors has directly contributed to the increased global incidence of cancer.

Patient expiry of major cancer biologics

The emergence of biosimilars due to patent expiration of biologics hinder the market growth, despite the increased incidence of cancer during the forecast period.

For the detailed list of factors that will drive and challenge the growth of the cancer biologics market during 2019-2023, view our report.

Competitive Landscape

The market appears to be highly concentrated with the presence of a few market players. Manufacturers in the global cancer biologics market are entering into strategic collaborations to develop or commercialize biologics indicated for the treatment of various types of cancer. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.


Press Release

Technavio Announces the Publication of its Research Report – Global Cancer biologics Market 2019-2023

Technavio recognizes the following companies as the key players in the global cancer biologics market: Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, and Merck & Co., Inc.

Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is the rise in strategic collaborations.”

According to the report, one of the major drivers for this market is the robust pipeline and new drug approvals.

Further, the report states that one of the major factors hindering the growth of this market is the late diagnosis and poor survival of patients with cancer.

Companies Mentioned

Amgen Inc.
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Merck & Co., Inc.

  • Executive summary
  • Scope of the report
    • Preface
    • Currency conversion rates for US$
  • Market landscape
    • Market ecosystem
      • Table Global oncology therapeutics market
      • Table Segments of global oncology therapeutics market
    • Market characteristics
      • Table Market characteristics
    • Market segmentation analysis
      • Table Market segments
  • Market sizing
    • Market definition
      • Table Market definition - Inclusions and exclusions checklist
    • Market sizing 2018
      • Table Market size 2018
    • Market size and forecast 2018-2023
      • Table Global market: Size and forecast 2018-2023 ($ millions)
      • Table Global market: Year-over-year growth 2019-2023 (%)
  • Five forces analysis
    • Table Five forces analysis 2018
    • Table Five forces analysis 2023
    • Bargaining power of buyers
      • Table Bargaining power of buyers
    • Bargaining power of suppliers
      • Table Bargaining power of suppliers
    • Threat of new entrants
      • Table Threat of new entrants
    • Threat of substitutes
      • Table Threat of substitutes
    • Threat of rivalry
      • Table Threat of rivalry
    • Market condition
      • Table Market condition - Five forces 2018
  • Market segmentation by product
    • Table Product - Market share 2018-2023 (%)
    • Comparison by product
      • Table Comparison by product
    • Monoclonal antibodies - Market size and forecast 2018-2023
      • Table Monoclonal antibodies - Market size and forecast 2018-2023 ($ millions)
      • Table Monoclonal antibodies - Year-over-year growth 2019-2023 (%)
    • Vaccines - Market size and forecast 2018-2023
      • Table Vaccines - Market size and forecast 2018-2023 ($ millions)
      • Table Vaccines - Year-over-year growth 2019-2023 (%)
    • Cell and gene therapy - Market size and forecast 2018-2023
      • Table Cell and gene therapy - Market size and forecast 2018-2023 ($ millions)
      • Table Cell and gene therapy - Year-over-year growth 2019-2023 (%)
    • Others - Market size and forecast 2018-2023
      • Table Others - Market size and forecast 2018-2023 ($ millions)
      • Table Others - Year-over-year growth 2019-2023 (%)
    • Market opportunity by product
      • Table Market opportunity by product
  • Customer landscape
    • Table Customer landscape
  • Geographic landscape
    • Geographic segmentation
      • Table Market share by geography 2018-2023 (%)
    • Geographic comparison
      • Table Geographic comparison
    • North America - Market size and forecast 2018-2023
      • Table North America - Market size and forecast 2018-2023 ($ millions)
      • Table North America - Year-over-year growth 2019-2023 (%)
    • Europe - Market size and forecast 2018-2023
      • Table Europe - Market size and forecast 2018-2023 ($ millions)
      • Table Europe - Year-over-year growth 2019-2023 (%)
    • Asia - Market size and forecast 2018-2023
      • Table Asia - Market size and forecast 2018-2023 ($ millions)
      • Table Asia - Year-over-year growth 2019-2023 (%)
    • ROW - Market size and forecast 2018-2023
      • Table ROW - Market size and forecast 2018-2023 ($ millions)
      • Table ROW - Year-over-year growth 2019-2023 (%)
    • Key leading countries
      • Table Key leading countries
    • Market opportunity
      • Table Market opportunity
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table Biologics in the pipeline for cancer
      • Table List of recently approved cancer biologics by the FDA
    • Market challenges
      • Table Cancer biologics and their biosimilar versions
      • Table Impact of drivers and challenges
  • Market trends
    • Table List of collaborations between manufacturers of cancer biologics
    • Table List of predictive biomarkers for cancer
  • Vendor landscape
    • Overview
      • Table Vendor landscape
    • Landscape disruption
      • Table Landscape disruption
  • Vendor analysis
    • Vendors covered
      • Table Vendors covered
    • Vendor classification
      • Table Vendor classification
    • Market positioning of vendors
      • Table Market positioning of vendors
    • Amgen Inc.
      • Table Amgen Inc. - Vendor overview
      • Table Amgen Inc. - Business segments
      • Table Amgen Inc. - Organizational developments
      • Table Amgen Inc. - Geographic focus
      • Table Amgen Inc. - Key offerings
    • Bristol-Myers Squibb Company
      • Table Bristol-Myers Squibb Company - Vendor overview
      • Table Bristol-Myers Squibb Company - Business segments
      • Table Bristol-Myers Squibb Company - Organizational developments
      • Table Bristol-Myers Squibb Company - Geographic focus
      • Table Bristol-Myers Squibb Company - Key offerings
    • Eli Lilly and Company
      • Table Eli Lilly and Company - Vendor overview
      • Table Eli Lilly and Company - Business segments
      • Table Eli Lilly and Company - Organizational developments
      • Table Eli Lilly and Company - Geographic focus
      • Table Eli Lilly and Company - Segment focus
      • Table Eli Lilly and Company - Key offerings
    • F. Hoffmann-La Roche Ltd
      • Table F. Hoffmann-La Roche Ltd - Vendor overview
      • Table F. Hoffmann-La Roche Ltd - Business segments
      • Table F. Hoffmann-La Roche Ltd - Organizational developments
      • Table F. Hoffmann-La Roche Ltd - Geographic focus
      • Table F. Hoffmann-La Roche Ltd - Segment focus
      • Table F. Hoffmann-La Roche Ltd - Key offerings
    • Merck & Co., Inc.
      • Table Merck & Co., Inc. - Vendor overview
      • Table Merck & Co., Inc. - Business segments
      • Table Merck & Co., Inc. - Organizational developments
      • Table Merck & Co., Inc. - Geographic focus
      • Table Merck & Co., Inc. - Segment focus
      • Table Merck & Co., Inc. - Key offerings
  • Appendix
    • Research methodology
      • Table Validation techniques employed for market sizing
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook